Drugs / FerroTrace
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT05899985 | Mar 2024 → May 2026 overdue | esophageal cancer, gastric cancer | Ferronova Pty Ltd | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FerroTrace | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05899985 ↗ |
| Modality | Diagnostic / imaging agent | “potential added diagnostic and clinical value of using the FerroTrace® and FerroMag Sentinel Lymph Node Mapping (SLNM) System” NCT05899985 ↗ |
| Route | Other | “FerroTrace will be injected peri-tumorally during the surgeons staging endoscopy” NCT05899985 ↗ |